T
Turid Aas
Researcher at Haukeland University Hospital
Publications - 64
Citations - 15205
Turid Aas is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 22, co-authored 56 publications receiving 14058 citations. Previous affiliations of Turid Aas include University of Bergen.
Papers
More filters
Journal ArticleDOI
Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer
Karin Collett,Geir Egil Eide,Jarle B. Arnes,Ingunn M. Stefansson,Johan Eide,Audun Braaten,Turid Aas,Ariel P Otte,Lars A. Akslen +8 more
TL;DR: Tissue microarray analysis of 190 breast carcinomas from a nested case-control study shows that EZH2 is significantly associated with interval breast cancers, and a strong relationship was found with tumor cell proliferation, locally advanced disease, metastasis at presentation, markers of the basal epithelial phenotype, and p53 status.
Journal Article
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Stephanie Geisler,Anne Lise Børresen-Dale,Hilde Johnsen,Turid Aas,Jürgen Geisler,Lars A. Akslen,Gun Anker,Per Eystein Lønning +7 more
TL;DR: The data suggest that mutations affecting this particular domain of the p53 protein may cause resistance to several different cytotoxic compounds applied in breast cancer treatment.
Journal ArticleDOI
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response
Emelyne Dejeux,Jo Anders Rønneberg,Jo Anders Rønneberg,Hiroko K. Solvang,Ida R. K. Bukholm,Stephanie Geisler,Turid Aas,Ivo Gut,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Per Eystein Lønning,Per Eystein Lønning,Vessela N. Kristensen,Vessela N. Kristensen,Jörg Tost +14 more
TL;DR: The DNA methylation status at the promoters of GSTP1, FOXC1 and ABCB1 correlated with survival, whereby the combination of methylated genes improved the subdivision with respect to the survival of the patients.
Journal ArticleDOI
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer
Therese Sørlie,Charles M. Perou,Cheng Fan,Stephanie Geisler,Turid Aas,Andrew B. Nobel,Gun Anker,Lars A. Akslen,David Botstein,Anne Lise Børresen-Dale,Per Eystein Lønning +10 more
TL;DR: A statistical analysis of large-scale gene expression patterns and their relationship to response following neoadjuvant chemotherapy in locally advanced breast cancers could not uncover a gene profile that could reliably predict response to either treatment regimen.
Journal ArticleDOI
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Jürgen Geisler,Hilgegunn Helle,Dagfinn Ekse,Nhat K. Duong,Dean B. Evans,Yngve Nordbø,Turid Aas,Per Eystein Lønning +7 more
TL;DR: The data reveals that letrozole is more effective compared with anastrozoles with respect to tissue as well as plasma estrogen suppression in patients with postmenopausal breast cancer.